| Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results NCT01179048 | Completed | P3 | Novo Nordisk A/S |
| Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes NCT02730377 | Completed | P4 | Novo Nordisk A/S |
| Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes NCT01336023 | Completed | P3 | Novo Nordisk A/S |
| The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes NCT01836523 | Completed | P3 | Novo Nordisk A/S |
| To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together NCT00318461 | Completed | P3 | Novo Nordisk A/S |
| Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes NCT00318422 | Completed | P3 | Novo Nordisk A/S |
| A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus NCT02501161 | Completed | P3 | Novo Nordisk A/S |
| The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes NCT00856986 | Completed | P3 | Novo Nordisk A/S |
| Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes NCT00614120 | Completed | P3 | Novo Nordisk A/S |
| The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes NCT02098395 | Completed | P3 | Novo Nordisk A/S |
| A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus. NCT02607306 | Completed | P3 | Novo Nordisk A/S |
| To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c NCT00294723 | Terminated | P3 | Novo Nordisk A/S |
| A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) NCT03172494 | Completed | P3 | Novo Nordisk A/S |
| The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus NCT00700817 | Completed | P3 | Novo Nordisk A/S |
| A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus. NCT02505334 | Completed | P3 | Novo Nordisk A/S |
| Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes NCT00331851 | Completed | P3 | Novo Nordisk A/S |
| Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes NCT00333151 | Completed | P3 | Novo Nordisk A/S |
| A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus NCT01952145 | Completed | P3 | Novo Nordisk A/S |
| A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus NCT02420262 | Completed | P3 | Novo Nordisk A/S |
| Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes NCT00518882 | Completed | P3 | Novo Nordisk A/S |
| A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD) NCT03175120 | Completed | P3 | Novo Nordisk A/S |
| The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes NCT01617434 | Completed | P3 | Novo Nordisk A/S |
| The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy NCT01676116 | Completed | P3 | Novo Nordisk A/S |
| The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy NCT01618162 | Completed | P3 | Novo Nordisk A/S |
| A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms NCT02298192 | Completed | P3 | Novo Nordisk A/S |
| A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus NCT02773368 | Completed | P3 | Novo Nordisk A/S |
| A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes NCT01392573 | Completed | P3 | Novo Nordisk A/S |
| Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin NCT01388361 | Completed | P3 | Novo Nordisk A/S |
| Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin NCT01907854 | Completed | P4 | Novo Nordisk A/S |
| Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes NCT01973231 | Completed | P4 | Novo Nordisk A/S |
| Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes NCT00393718 | Completed | P3 | Novo Nordisk A/S |
| Saxenda in Obesity Services (STRIVE Study) NCT03036800 | Completed | P4 | University of Leicester |
| The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes NCT02008682 | Completed | P4 | Novo Nordisk A/S |
| Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone NCT01512108 | Completed | P3 | Novo Nordisk A/S |
| The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification NCT01664247 | Completed | P3 | Novo Nordisk A/S |
| Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes NCT01917656 | Completed | P4 | Novo Nordisk A/S |
| A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function NCT02443155 | Completed | P2 | Novo Nordisk A/S |
| LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors. NCT02964247 | Completed | P3 | Novo Nordisk A/S |
| Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment NCT01620489 | Completed | P3 | Novo Nordisk A/S |
| Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes NCT00395746 | Completed | P3 | Novo Nordisk A/S |
| Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes NCT01572740 | Completed | P3 | Novo Nordisk A/S |
| Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes NCT00154414 | Completed | P2 | Novo Nordisk A/S |
| Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent NCT01511198 | Completed | P2 | Novo Nordisk A/S |
| A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs NCT02911948 | Completed | P3 | Novo Nordisk A/S |
| Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease NCT04146155 | Unknown | P4 | Second Affiliated Hospital, Zhejiang University, School of Medicine |
| Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes NCT01509755 | Completed | P2 | Novo Nordisk A/S |
| Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes NCT00154401 | Completed | P2 | Novo Nordisk A/S |
| A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004) NCT02492763 | Terminated | P2 | Merck Sharp & Dohme LLC |
| The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study NCT01966978 | Completed | P4 | University of Texas Southwestern Medical Center |
| Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM) NCT01234649 | Completed | P3 | Woman's |
| Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes NCT01511172 | Completed | P2 | Novo Nordisk A/S |
| IDegLira HIGH Trial NCT03737240 | Completed | P3 | Emory University |
| Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes NCT01541215 | Completed | P3 | Novo Nordisk A/S |
| A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin NCT02205528 | Completed | P2 | Novo Nordisk A/S |
| The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes NCT01795248 | Completed | P4 | Tina Vilsboll |
| The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus NCT00620282 | Completed | P3 | Novo Nordisk A/S |
| Liraglutide as add-on to Insulin in Type 1 Diabetes NCT02092896 | Completed | P3 | Hvidovre University Hospital |
| Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes NCT01508949 | Completed | P2 | Novo Nordisk A/S |
| A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification NCT02100475 | Completed | P3 | Novo Nordisk A/S |
| Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes NCT00993720 | Completed | P2/P3 | Hvidovre University Hospital |